From Name:
From Email:
To Name:
To Email:

Optional Message:


Heat Biologics, University Of Miami Announce Zika Vaccine Collaboration

from Clinical Leader

Heat Biologics, Inc., a leader in the development of gp96-based immunotherapies that activate a patient's immune system to fight cancer, announced that it has entered into an agreement with the University of Miami for the license and development of a portfolio of patents leveraging its gp96 platform to target the Zika virus and other infectious diseases. Heat has formed a wholly-owned subsidiary, Zolovax, Inc., to focus on the development of gp96-based vaccines targeting Zika, HIV, West Nile, dengue and yellow fever. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063